AbCellera Biologics opened lower at $11.62, compared with its previous close of $11.95. In the last trading session, the stock traded between $11.24 and $12.01. It showed a downward intraday trend.
An investment of $100 made 5 years ago in AbCellera Biologics is now worth
$ 77.19
Resulting in a loss of
$ 22.81 (22.81%)
Note: Past profits do not guarantee future returns.
Rating from 8 Analysts
Today's Change
$-0.33 (-2.79%)
Day High
$12.01
Day Low
$11.24
Day Open
$11.62
Prev Close
$11.95
Volume
28,76,157
1W Return
-5.38%
1M Return
-8.20%
3M Return
19.16%
6M Return
121.28%
1Y Return
189.70%
Market Cap ($ Mn)
3,794
PE Ratio
-
PB Ratio
3.88
PEG Ratio
-
ROE
-14.59%
ROCE
-15.92%
EPS (TTM)
$-0.12
1 Week
-5.38%
1 Month
-8.20%
3 Months
19.16%
6 Months
121.28%
9 Months
271.15%
AbCellera Biologics Q3FY26 Results: Net loss narrows to $41M, revenue up 11%
Net loss narrowed to $41 million in Q3FY26 from $57 million in Q3FY25. Revenue increased to over $10 million, up approximately 11% YoY. SG&A expenses dropped 44% to $14 million following litigation conclusion. Company raised $200 million, boosting cash reserves to over $790 million. Lead candidate ABCL635 moves toward late-stage development in 2027.
3 days agoAbCellera to report Q3 2026 financial results on November 9
AbCellera Biologics will release Q3 2026 results on November 9, 2026. Earnings conference call scheduled for 3:00 pm Pacific Time. Live webcast and replay available via Investor Relations website.
1mo agoAbCellera to present ABCL635 Phase 2 data at IMS 20th World Congress
AbCellera to present interim Phase 2 data for ABCL635 at IMS 20th World Congress. Presentation scheduled for October 1, 2026, in Rio de Janeiro. Data covers efficacy and safety in postmenopausal women with vasomotor symptoms. ABCL635 is a first-in-class NK3R monoclonal antibody targeting hot flashes.
1mo agoAbCellera Biologics stock rises 15.83% amid Jazz Pharmaceuticals FDA win
AbCellera Biologics shares rose 15.83% to $12.29 on Tuesday, with the stock up over 250% year-to-date. The move followed FDA approval of Jazz Pharmaceuticals' two Ziihera-containing combination regimens for HER2-positive gastroesophageal adenocarcinoma. AbCellera and Jazz Pharmaceuticals have a collaboration involving $56 million in upfront payments and up to $792 million in potential milestone payments. The RSI stands at 82.82, signaling an overbought condition, while MACD remains above its signal line. AbCellera Biologics has delivered a 185.12% return over the past 12 months.
2mo agoAbCellera prices oversubscribed $200M share offering at $9.75
AbCellera Biologics Inc. priced an oversubscribed $200 million share offering at $9.75 per share. The deal includes 17.4 million common shares and pre-funded warrants, with proceeds funding pipeline development including lead asset ABCL635.
3mo agoAbCellera shares rise 33% on ABCL635 data, raises $200M
AbCellera Biologics shares surged 33.26% after ABCL635 cut hot flash frequency by 83% in Phase 2 trials. The company launched a $200 million stock offering to fund pipeline development. Analysts maintain Buy ratings with targets ranging from $9 to $30.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in AbCellera Biologics is now worth
$ 77.19
Resulting in a loss of
$ 22.81 (22.81%)
Note: Past profits do not guarantee future returns.
